CeriBell (CBLL) Stock Price, News & Analysis

Company Overview

CeriBell, Inc. develops medical technology designed to make electroencephalography (EEG) more accessible in acute-care settings. Its primary product is the Ceribell Rapid Response EEG system, a portable, point-of-care platform that enables clinicians to record and assess brain activity at the bedside, including when evaluating patients for seizures and status epilepticus.

The Ceribell system combines a simplified EEG headband and recording device with software that supports rapid interpretation. The platform also incorporates artificial-intelligence-based seizure detection tools intended to help healthcare professionals identify abnormal brain activity and make more timely clinical decisions.

Founded in 2015, CeriBell serves hospitals and other healthcare providers, with a focus on emergency departments, intensive care units and other settings where conventional EEG testing may not be immediately available. The company is headquartered in Sunnyvale, California, and markets its products primarily in the United States.

Key Stats

• Today's Range: $23.32 to $24.19
• 50-Day Range: $17.65 to $25.04
• 52-Week Range: $10.85 to $25.63
• Volume: 305,317 shs
• Average Volume: 336,904 shs
• Market Capitalization: $909.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.00
• Consensus Rating: Moderate Buy

CeriBell Stock Analysis - MarketRank™

CeriBell scored higher than 55% of companies evaluated by MarketBeat, and ranked 429th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CeriBell has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

CeriBell has a consensus price target of $27.00, representing about 14.0% upside from its current price of $23.69.

Amount of Analyst Coverage

CeriBell has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CeriBell are expected to grow in the coming year, from ($1.96) to ($1.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CeriBell is -13.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CeriBell is -13.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CeriBell has a P/B Ratio of 5.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.76% of the float of CeriBell has been sold short.

Short Interest Ratio / Days to Cover

CeriBell has a short interest ratio ("days to cover") of 6.12.

Change versus previous month

Short interest in CeriBell has recently decreased by 4.61%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CeriBell does not currently pay a dividend.

Dividend Growth

CeriBell does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.56

News Sentiment

CeriBell has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for CeriBell this week, compared to 5 articles on an average week.

MarketBeat Follows

1 people have added CeriBell to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CeriBell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,089,095.00 in company stock.

Percentage Held by Insiders

17.70% of the stock of CeriBell is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

CeriBell has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CBLL
• Previous Symbol: NASDAQ:CBLL
• CIK: 1861107
• Web: www.ceribell.com
• Phone: (800) 436-0826
• Fax: N/A
• Employees: 300
• Year Founded: 2014

Price Target and Rating

• Average Price Target for CeriBell: $27.00
• High Price Target: $33.00
• Low Price Target: $17.00
• Potential Upside/Downside: +14.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.41 million
• Net Margins: -64.73%
• Pretax Margin: -64.73%
• Return on Equity: -44.85%
• Return on Assets: -35.69%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 9.18
• Quick Ratio: 8.79

Sales & Book Value

• Annual Sales: $89.06 million
• Price / Sales: 10.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.19 per share
• Price / Book: 5.65

Miscellaneous

• Outstanding Shares: 38,380,000
• Free Float: 31,585,000
• Market Cap: $909.22 million
• Optionable: N/A
• Beta: 0.94